Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Medicare coverage for biologic therapies -- a mainstay of treatment for rheumatoid arthritis-- has been in flux recently. Medicare Part B coverage for biologic therapy ended in 2004, and the Medicare ...

Two posters presented at the American College of Allergy, Asthma and Immunology 2023 Annual Scientific Meeting evaluated real-world biologic utilization for patients with severe, uncontrolled asthma.

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Please provide your email address to receive an email when new articles are posted on . Nearly half of surveyed primary care physicians reported unawareness of biologics for asthma. A majority of ...

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...

Early initiation of biologic therapy in patients with Crohn’s disease (CD) is associated with higher rates of transmural healing and leads to improved long-term outcomes. In CD, early initiation of ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

Please provide your email address to receive an email when new articles are posted on . Biologic therapies are underutilized in non-white populations. By identifying barriers to specific biologic ...

Whereas natural tolerance rates are generally high for common allergens, such as eggs, milk, and wheat, allergies to other foods often persist beyond childhood. For instance, approximately 72.2% of ...